Treatment options for Primary CNS Lymphoma by Laghari, Abid et al.
eCommons@AKU
Section of Haematology/Oncology Department of Medicine
March 2018
Treatment options for Primary CNS Lymphoma
Abid Laghari
Aga Khan University, abid.laghari@aku.edu
Syed Ijlal Ahmed
Aga Khan University
Adnan Jabbar
Aga Khan University, adnan.jabbar@aku.edu
Muhammad Shahzad Shamim
Aga Khan University, shahzad.shamim@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_med_haematol_oncol
Part of the Cardiology Commons, Oncology Commons, and the Surgery Commons
Recommended Citation
Laghari, A., Ahmed, S. I., Jabbar, A., Shamim, M. (2018). Treatment options for Primary CNS Lymphoma. JPMA. The Journal of the
Pakistan Medical Association, 68(3), 499-500.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/40
Abstract
Primary CNS lymphoma (PCNSL) is a rare and aggressive
brain tumour that is uniformly fatal. The rarity of the
disease and the poor response to treatment makes it
difficult to reach a consensus with regards to treatment
options. In this review, the authors have discussed
different treatment modalities used in the management
of PCNSL including chemotherapy, surgery and radiation,
as well as the results of recent clinical trials on treatment
options for PCNSL.
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Introduction
The incidence of primary CNS lymphoma (PCNSL) has been
on the rise since the 1970s, even in immuno-competent
patients. The risk is 2-6% in patients with acquired
immunodeficiency syndrome, and will probably increase
with improving life expectancy in these patients.
Transplant patients have a cumulative risk of 1-5% for
developing PCNSL. Similarly, patients with congenital
immune deficiency carry a risk of 4%. Moreover, PCNSL may
also present as a secondary malignancy. In addition to age
and performance status, which are well known prognostic
factors, symptoms, tumour volume, presence of meningeal
dissemination and serum LDH level also significantly
influence survival in these patients.1 Chemo-radiation
therapy has remained the mainstay of management in
patients with PCNSL and is associated with reasonable
efficacy but with high incidence of neurotoxicity. As a
consequence, a difficulty in PCNSL treatment is the choice
between strategies designed to intensify therapy to
improve the cure rate, versus strategies of treatment de-
escalation to avoid severe neurotoxicity.2 In this review, the
authors have discussed the various options for the
management of PCNSL including chemotherapy, surgery
and radiation therapy, alone or in combination.
Review of Evidence
Primary CNS lymphoma was conventionally treated by
corticosteroids and whole brain radiotherapy (WBRT). In
1990, Deangelis et al., introduced a protocol that included
intrathecal and systemic methotrexate along with cranial
radiotherapy. This vigorous multi-modality regimen
showed improved survival rate over conventional
therapy.3 Ferreri et al., based their phase II trial on
MATILDE regimen which included high dose
methotrexate combined with CNS penetrating
chemotherapeutic agents (cytarabine, idarubicin and
thiotepa) followed by response tailored radiotherapy.
They concluded that this regimen increased the survival
with reduction in neurological adverse effects of WBRT
and intrathecal chemotherapy.4 Follow up of this trial also
supported the initial findings and suggested an
improvement in disease remission at 12 years.5 In another
study, authors concluded that intra-venous nimustine
(ACNU), a drug that crosses the blood brain barrier,
combined with WBRT improved the survival of
immunocompetent patients with PCNSL. However, it was
associated with bone marrow suppression and late onset
neurotoxicity especially in elderly population.6
Ghesquieres et al., in a prospective multicenter trial also
showed that combination therapy in the form of C5R
protocol (methotrexate, doxorubicin, vincristine,
cyclophosphamide and cytarabine with XRT) is a better
management option for younger immunocompetent
patients but the results were not promising in elderly
population because of leukoencephalopathy and
cognitive decline.7 Morris et al., also found combination
therapy as a superior option, and used rituximab,
methotrexate, procarbazine, vincristine for induction and
then consolidation with reduced dose of XRT and
cytarabine with high response rate, long term disease
control and minimal neurotoxicity.8 Hirono et al.,
suggested that stereotactic radiosurgery followed by high
dose methotreaxate improves overall survival with the
preservation of daily activities compared to WBRT in
newly diagnosed PCNSL.9
The recently published trial assessed the tolerability and
efficacy of adding rituximab with or without thiotepa to
methotrexate-cytarabine combination therapy (the
MATRix regimen), followed by a second randomization
comparing consolidation with whole-brain radiotherapy
or autologous stem cell transplantation in patients with
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primary CNS lymphoma. With the limitations of a
randomized phase 2 study design, the IELSG32 trial
provides a high level of evidence supporting the use of
MATRix combination as the new standard chemo-
immunotherapy for patients aged up to 70 years with
newly diagnosed primary CNS lymphoma and as the
control group for future randomized trials.10 In a
prospective observational cohort study, Alvarez-Pinzon et
al., compared high dose methotrexate alone with
combination of high dose methotrexate and SRS. They
concluded that combination therapy is useful in local
control of the newly diagnosed or relapsed cases without
significant neurotoxicity.11
Conventionally, the role of surgery is limited to biopsy of
the lesion for histopathological diagnosis. However,
recently Sonabend et al., suggested surgical resection as
an alternative treatment option in selected patients. In
their series, even though the complication rates were
comparable to other intracranial high-grade lesions, the
authors were not able to prove the superiority of surgery
to other therapeutic modalities in the treatment of
PCNSL.12
Conclusion
There appear variations in the management of PCNSL and
preferences dictate the use of methotrexate, other
chemotherapeutics, and radiotherapy as management
options. Most authors have advocated combination of
chemotherapy and radiotherapy more successful than
any of these treatments alone. The role of stereotactic
radiosurgery as co-adjuvant with methotrexate is also
emerging as useful tool in disease control, better survival
and lesser complications in recent studies. It is of
significant value that better survival rates of PCNSL
patients can be obtained by employing multidisciplinary
treatment options.
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Figure: MRI brain T1WI with gadolinum enhancement showing large enhancing
abnormal signal intensity lesion in the right occipital lobe involving part of splenium of
corpus callosum and wrapping the right occipital horn. Later, neuronavigation guided
stereotactic biopsy proved PCNSL.
